Do vancomycin serum levels predict failures of vancomycin therapy or nephrotoxicity in cancer patients?

Journal of Chemotherapy

Volumn 9, Issue 6, 1997, Pages 420-426

  Kralovicova K ^a,c   Spanik, S ^a,b   Halko, J ^a,b   Netriova, J ^a   Studena Mrazova, M ^a   Novotny, J ^a,b   Grausova, S ^a,b   Koren, P ^b   Krupova, ^b   Demitrovicova, A ^a   Kukuckova, E ^a   Krcmery Jr , V ^a  

^a CANCER RESEARCH INSTITUTE   (Slovakia)

^b TRNAVA UNIVERSITY   (Slovakia)

^c Heydukova 10   (Slovakia)

Author keywords

Enterococci; Nephrotoxicity; Serum levels; Staphylococci; Vancomycin

Indexed keywords

AMINOGLYCOSIDE; AMPHOTERICIN B; CISPLATIN; FLUCONAZOLE; OFLOXACIN; PENICILLIN V; VANCOMYCIN;

ACUTE LEUKEMIA; ARTICLE; BACTEREMIA; BACTERIAL INFECTION; CANCER PATIENT; CASE CONTROL STUDY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; ENTEROCOCCUS; GRAM POSITIVE BACTERIUM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; NEPHROTOXICITY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PROGNOSIS; RISK FACTOR; STAPHYLOCOCCUS; TREATMENT FAILURE;

EID: 17344394615     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.1997.9.6.420     Document Type: Article

References (14)

1. EORTC Antimicrobial Study group. Grampositive bactcremia in cancer patients from studies on empiric therapy of fever and ncutropenia. Eur J Clin Microbiol Infect Dis 1993; 10, 4: 366-372.
2. EORTC Antimicrobial Therapy Cooperative group. Piperacillin/tazobactam plus amikacin versus ceftazidime plus amikacin in empiric therapy of febrile neutropenia in cancer patients. 33rd ICAAC, Annaheim, 1992, Abstr. 1143.
3. EORTC Antimicrobial Therapy Cooperative group. Amikacin plus ccftriaxone once daily versus in multiple daily doses in empiric therapy for febrile granulocytopenic patients. Ann Infect Med 1993; 117, 6: 377-382.
4. EORTC Antimicrobial Therapy Cooperative group. Meropenem versus ceftazidime plus amikacin in initial therapy of infections in febrile neutropenia. 34th ICAAC, Orlando, 1996, Abstract No. 898.
5. EORTC Antimicrobial Therapy Cooperative group. Pefloxacin plus penicillin in prevention of infections in granulocytopenic patients. A randomized placebo-controlled trial. JAMA 1995; 69, 4: 288-296.
6. Murray B. Vancomycin resistance in enterococci. Clin Infect Dis 1995; 20, 2: 35-39.
7. Kline MW, Mason EO. Methicillin-resistant S. atiretis: pédiatrie perspective. Pediatr Clin North Am 1988; 35, 7: 613-624.
8. Guiot JWE. Bacteremia due to penicillin-resistant viridans streptococci in cancer patients. Clin Infect Dis 1995; 20, 2: 107-113.
9. Menichctti F, Del Favcro A. The role of grampositive therapy in the neutropenic patient. J Antimicrob Chemother 1991; 27: 51-60.
10. VC'elty TE, Copa AK. Impact of vancomycin therapeutic drug monitoring on particular care. Ann Pharmacothcr 199-4; 24: 1335-1339.
11. Krcmcry V Jr, Trupl J. Breakthrough bacteremia due to vancomycin-resistant S. epidermidis in cancer patients after quinolone prophylaxis. Eur J Clin Microbiol Infect Dis 1996; 12, 1: 28-33.
12. Chang R, Lieu L, Magalowkin M. A prospective study of vancomycin pharmacokinctics and dosage requirements in pédiatrie cancer patients. Pediatr Infect Dis J 1994; 13: 969974.
13. " Pryka R. Vancomycin serum concentration monitoring a combined debate. Ann Pharmacother 1994; 28: 1397-1399.
14. Saunders NJ. Why monitor peak vancomycin serum concentrations? Lancet 1994; 344: 1748-1750.